

Department of Pharmacology, EA 4650, Normandie University, University of Caen Normandy, Caen, France (Dolladille, Alexandre); CHU de Caen Normandie, Department of Pharmacology, Caen, France (Dolladille, Alexandre); Centre Francois Baclesse Centre de Lutte Contre le Cancer (Cancer Centre), Caen, France (Da-Silva).

**Corresponding Author:** Charles Dolladille, MD, MSc, PICARO Cardio-oncology Program, UNICAEN, Centre Hospitalier Universitaire (CHU) de Caen Normandie, Department of Pharmacology, Normandie University, Avenue de la Côte de Nacre, F-14000 Caen, France ([dolladille-c@chu-caen.fr](mailto:dolladille-c@chu-caen.fr)).

**Published Online:** September 24, 2020. doi:[10.1001/jamaoncol.2020.3960](https://doi.org/10.1001/jamaoncol.2020.3960)

**Conflict of Interest Disclosures:** None reported.

1. Dolladille C, Ederhy S, Sassier M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. *JAMA Oncol.* 2020;6(6):865-887. doi:[10.1001/jamaoncol.2020.0726](https://doi.org/10.1001/jamaoncol.2020.0726)
2. Bomze D, Hasan Ali O, Bate A, Flatz L. Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden. *JAMA Oncol.* 2019;5(11):1633-1635. doi:[10.1001/jamaoncol.2019.3221](https://doi.org/10.1001/jamaoncol.2019.3221)
3. Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. *JAMA Oncol.* 2019;5(9):1310-1317. doi:[10.1001/jamaoncol.2019.1022](https://doi.org/10.1001/jamaoncol.2019.1022)
4. Abu-Sbeih H, Ali FS, Naqash AR, et al. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. *J Clin Oncol.* 2019;37(30):2738-2745. doi:[10.1200/JCO.19.00320](https://doi.org/10.1200/JCO.19.00320)
5. Santini FC, Rizvi H, Plodkowski AJ, et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. *Cancer Immunol Res.* 2018;6(9):1093-1099. doi:[10.1158/2326-6066.CIR-17-0755](https://doi.org/10.1158/2326-6066.CIR-17-0755)

## CORRECTION

**Error in Author Name:** The Original Investigation titled, "Characterization of the Cancer Spectrum in Men With Germline *BRCA1* and *BRCA2* Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA),"<sup>1</sup> published in the August 2020 print issue of *JAMA Oncology*, included an error in an author's name. Her name should appear as Joanne Ngeow, MBBS. This article was corrected online.

1. Silvestri V, Leslie G, Barnes DR, et al; and the CIMBA Group. Characterization of the cancer spectrum in men with germline *BRCA1* and *BRCA2* pathogenic variants: results from the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA). *JAMA Oncol.* 2020;6(8):1218-1230. doi:[10.1001/jamaoncol.2020.2134](https://doi.org/10.1001/jamaoncol.2020.2134)

**Error in Coauthor's Name:** The Original Investigation titled "Global Retinoblastoma Presentation and Analysis by National Income Level,"<sup>1</sup> published in the May 2020 issue of *JAMA Oncology*, contained an error in a coauthor's name. The correct spelling is Usama Al-Jumaily. This article was corrected online.

1. Fabian ID, Abdallah E, Abdullahi SU, et al; Global Retinoblastoma Study Group. Global retinoblastoma presentation and analysis by national income level. *JAMA Oncol.* 2020;6(5):685-695. doi:[10.1001/jamaoncol.2019.6716](https://doi.org/10.1001/jamaoncol.2019.6716)

**Incorrect Supplement Version:** The article "Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial,"<sup>1</sup> published in the May issue of *JAMA Oncology*, included an incorrect version of online Supplement 1. The correct version has been uploaded, and the Supplement is now correct online.

1. Rizvi NA, Cho BC, Reinmuth N, et al; MYSTIC Investigators. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. *JAMA Oncol.* 2020;6(5):661-674. doi:[10.1001/jamaoncol.2020.0237](https://doi.org/10.1001/jamaoncol.2020.0237)